Stick or twist: everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
As the coronavirus disease 2019 (COVID-19) pandemic continues globally, protecting the health of vulnerable people with epilepsy (PWE) remains a priority. Many people with tuberous sclerosis complex (TSC) reside in long-term care facilities (LTCFs), which are high risk settings for infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and severe COVID-19 . Pre-existing respiratory disease is associated with an increased risk of severe COVID-19, which may be relevant to those with lymphangioleiomyomatosis (LAM), a progressive cystic lung disease infrequently seen in women with TSC .
RCSI – Blackrock Clinic StAR MD programme, 2020
CommentsThe original article is available at https://www.sciencedirect.com/
Published CitationMoloney PB, Delanty N. Stick or twist: everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic. Seizure. 2021 ;91:271-272.
Publication Date4 July 2021
- FutureNeuro Centre
- Beaumont Hospital
- School of Pharmacy and Biomolecular Sciences
- Neurological and Psychiatric Disorders
- Accepted Version (Postprint)